CCIA
IMNM icon

Campbell & Co Investment Adviser’s Immunome IMNM Stock Holding History

Campbell & Co Investment Adviser’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$564K Buy
26,605
+8,592
+48% +$184K 0.03% 730
2026
Q1 		$394K Buy
+18,013
New +$401K 0.02% 806

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Campbell & Co Investment Adviser's IMNM Position: Q2 2026 in Review

Campbell & Co Investment Adviser increased its Immunome (IMNM) stake by 48% in Q2 2026, buying an estimated $184K and bringing the position to 26,605 shares worth $564K. The position accounts for 0.03% of the portfolio, ranked #730.

Campbell & Co Investment Adviser first reported a position in IMNM in Q1 2026 and has held it in 2 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Campbell & Co Investment Adviser held 26,605 shares of Immunome worth $564K as of Q2 2026.
  • Campbell & Co Investment Adviser bought 8,592 Immunome shares in Q2 2026, an estimated $184K.
  • Immunome made up 0.03% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #730 holding.
  • Campbell & Co Investment Adviser first reported a position in Immunome in Q1 2026 and has held it in 2 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.